{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_29", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-6 19:50:48", "close_timestamp": 1638820248070, "created": "06/12/2021 19:50:50", "department": "Media and Communications", "disability": false, "ease": 5, "environment": "production", "experiment_date_datepicker": "2021-12-06", "gender": "female", "id": "7cc767a9-f75e-4aa9-b240-8faa8b8fd264", "open_date_time": "2021-11-6 19:42:56", "open_timestamp": 1638819776169, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "Ivermectin, an already established FDA approved anti-parasitic drug has been found to kill COVID-19 within 48 hours. In a study led by Monash University, the drug has been show to kill COVID-19 cell cultures within 48 hours and seems to be promising as a treatment choice as a vaccine is being developed.", "task_condition": "text", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 471901, "what": "The story is about the discovery that an established anti-parasitic drug can kill COVID-19 cell cultures in under 48 hours", "when_happened": "few_years_ago", "where_location": "The story takes place in Australia.", "who": "Everyone in the world concerned about covid-19, University of Melbourne, Dr Kylie Wagstaff, Royal Melbourne Hospital, Monash Biomedicine Discovery Institute, Doherty Institute", "why": "The story is important as it is positive news in a world where a vaccine for an aggressive virus does not yet exist. It is positing hope as a cure seems to be very within reach, with relief coming in a form of an already established drug. "}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_29", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-6 19:27:44", "close_timestamp": 1638818864436, "created": "06/12/2021 19:27:48", "department": "Media and Communications", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-06", "gender": "female", "id": "4d6c2875-edfb-4a24-aefe-3708244d7fc8", "open_date_time": "2021-11-6 19:16:17", "open_timestamp": 1638818177835, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "Novavax' COVID-19 vaccine has faced challenges in its developments but its company is working very hard to get its vaccine globally distributed. Medical trials have shown positive efficacy as well as effectiveness on different strains of the virus. It has a practical number of doses required for each individual and seem to fare well for possible COVID-19 variants. It is working towards international approval and plans to ship hundreds of millions of doses to countries like India.", "task_condition": "viz", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 686601, "what": "The story is about whether the Noravax COVID-19 vaccine would be effective and safe for mass distribution", "when_happened": "few_month_ago", "where_location": "It takes place in the USA", "who": "Nasdaq (who might be the company developing this vaccine)", "why": "It is important because it is a matter of public health."}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_29", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-6 19:15:52", "close_timestamp": 1638818152519, "created": "06/12/2021 19:15:56", "department": "Media and Communications", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-06", "gender": "female", "id": "e31ec5df-fd86-4c97-85ea-0c55c8102ede", "open_date_time": "2021-11-6 19:2:6", "open_timestamp": 1638817326802, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "The Australian government is urging GPs to prescribe ivermectin triple therapy to fight COVID-19. After much research, studies have shown that the drug, comprising zinc and doxycycline, has been shown to be effective in relieving severe symptoms of COVID-19. Australia is the first country to approve of Ivermectin triple therapy, which has been proven to show improvement in patients suffering from COVID-19. It is a good option for people who are infected, and could save lives.", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 825717, "what": "The story is about the Australian government urging Australian GPs to use ivermectin triple therapy to fight COVID-19, and to assure readers/Australians about the safety of the drug.", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Australian government", "why": "People are concerned about medicine and their wellbeing in a pandemic, and the article is relaying to readers of the drug's nature and that it has been well researched, to boost national confidence in Australia's ability to care for its citizens. "}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_29", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-6 19:42:7", "close_timestamp": 1638819727976, "created": "06/12/2021 19:42:10", "department": "Media and Communications", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-06", "gender": "female", "id": "fc238907-be9d-4a00-8048-a8ac5d7478e4", "open_date_time": "2021-11-6 19:28:8", "open_timestamp": 1638818888643, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Japan is the first country to authorise COVID-19 cocktail Ronapreve, which was developed by Roche majority-owned Japanese drugmaker Chugai Pharmaceutical. The antibody cocktail which is used intravenously has shown to improve survival in high-risk, non-hospitalized COVID-19 patients by reducing the risk of hospitalization and death. It has also been promising even up against other strains like the Delta Variant.", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 839333, "what": "The story is about the approval of a medicine (Ronapreve) to treat COVID-19 in high risk non hospitalised patients, and who created/approved the medicine. Therefore its validity is confirmed and this comforts readers in the name of public health.", "when_happened": "few_years_ago", "where_location": "Japan", "who": "High-risk non-hospitalized COVID-19 patients, Japanese government, Swiss pharma giant Roche, US biotech Regeneron, Chugai Pharmaceutical", "why": "The story is important as it is encouraging in a time where everything seems hopeless and depressing. Aside from informing readers about the approved medicine, its validity is confirmed and this comforts readers in the name of public health."}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_29", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-6 20:30:19", "close_timestamp": 1638822619332, "created": "06/12/2021 20:30:20", "department": "Media and Communications", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-06", "gender": "female", "id": "c9eb72fa-a498-42b0-8aa8-778da508c3d1", "open_date_time": "2021-11-6 20:13:48", "open_timestamp": 1638821628438, "summary": "Due to falling levels of vaccine acceptance globally, Pfizer initiated a study of their coronavirus vaccine in children aged 6-12. As children are a demographic not heavily affected by severe symptoms of COVID-19, the virus can be transmitted between more discreetly. Therefore, if left unchecked and uninvestigated, infection rates could rocket just between children, who will then infect their caregivers and adults around them. Public trust in vaccines have been shaky with mixed messaging from public health boards and politicians, as well as confusion over public health data.", "task_condition": "text", "task_key": "pfizer", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 990894}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_29", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-6 20:13:16", "close_timestamp": 1638821596798, "created": "06/12/2021 20:13:18", "department": "Media and Communications", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-06", "gender": "female", "id": "0ca69db1-56ad-49b2-8726-7e6bb682b8e0", "open_date_time": "2021-11-6 19:51:14", "open_timestamp": 1638820274950, "summary": "The European medicines Agency has concluded in April 2021 that unusual blood clots with low blood platelets should be listed as very rare side effects of the COVID-19 AstraZeneca vaccine. As of two weeks ago, 62 cases of cerebral venous sinus thrombosis and 24 cases of splanchnic vein thrombosis were reported, 18 of which were fatal.\r\n\r\nAstraZeneca still proves to be effective, as its positives outweigh these rare side effects, which may be associated with immune responses within individual patients. People below the age of 30 are recommended to get alternative vaccines to AstraZeneca, but those who have received their first dose should continue on with their second.", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 1321848}}}